This document is an update of the joint guidance that was published in 2011 by the European Centre for Disease Prevention and Control (ECDC) and the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA).
This report is based on the findings from two focused After-Action reviews (AARs) in Norway and Georgia that discussed the use of evidence in the advice-making process for long-term care facilities (LTCFs) during the start of the COVID-19 Omicron wave in early 2022.
This handbook provides an overview of commonly used laboratory protocols for the characterisation of SARS-CoV-2 and influenza viruses, provided by the AURORAE consortium.
This after-action review (AAR) investigates the use of evidence in Sweden’s advice-making process for distance learning during the period November 2020 to April 2021 (the focus period) in response to the SARS-CoV-2 (COVID-19) pandemic.
This document describes a risk-based targeted approach to identifying possible avian influenza virus infections through established routine respiratory virus surveillance systems during the winter season 2023/24.
Tuberculosis (TB) is a major cause of morbidity and mortality in Europe. High-quality laboratory diagnosis of TB is the basis for both individual patient treatment and surveillance.
This document provides an update on the safety of substances of human origin (SoHO) in relation to COVID-19. It reassesses the risk and proposes revised mitigation measures for preventing transmission through SoHO.